Last reviewed · How we verify
Estradiol + Medroxy Progesterone Acetate
This combination provides estrogen replacement and progestin supplementation to manage menopausal symptoms and prevent endometrial hyperplasia.
This combination provides estrogen replacement and progestin supplementation to manage menopausal symptoms and prevent endometrial hyperplasia. Used for Menopausal vasomotor symptoms (hot flashes, night sweats), Vulvovaginal atrophy, Prevention of postmenopausal osteoporosis.
At a glance
| Generic name | Estradiol + Medroxy Progesterone Acetate |
|---|---|
| Sponsor | Erasmus Medical Center |
| Drug class | Hormone replacement therapy (HRT) |
| Target | Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ), Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | FDA-approved |
Mechanism of action
Estradiol is a bioidentical estrogen that binds to estrogen receptors (ERα and ERβ) to alleviate vasomotor symptoms, vaginal atrophy, and bone loss associated with menopause. Medroxyprogesterone acetate (MPA) is a synthetic progestin that protects the endometrium from unopposed estrogen stimulation, reducing the risk of endometrial hyperplasia and cancer in women with an intact uterus.
Approved indications
- Menopausal vasomotor symptoms (hot flashes, night sweats)
- Vulvovaginal atrophy
- Prevention of postmenopausal osteoporosis
Common side effects
- Breast tenderness
- Headache
- Nausea
- Vaginal bleeding/spotting
- Bloating
- Mood changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: